Benjamin L. Oakes is the President and CEO at Scribe Therapeutics and a co-founder of the company.
Benjamin L. Oakes is the President and CEO at Scribe Therapeutics and a co-founder, President and CEO atof Scribethe Therapeuticscompany.
Benjamin L. Oakes received a Ph.D. in MolecularMolecular and Cellular Biology from UC Berkeley in 2017, where he worked on developing CRISPR-Cas9 molecules with enhanced characteristics. Two projects originating from these research produced distinct versions of synthetic sensing systems capable of modifying nucleic acids only when triggered by external stimuli and have been applied in further research as well as pragmatically applied technologies.
Benjamin L. Oakes is the co-founder, President and CEO at Scribe Therapeutics.
Benjamin L. Oakes received a Ph.D. in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked on developing CRISPR-Cas9 molecules with enhanced characteristics. Two projects originating from these research produced distinct versions of synthetic sensing systems capable of modifying nucleic acids only when triggered by external stimuli and have been applied in further research as well as pragmatically applied technologies.
Benjamin L. Oakes is the President and CEO at Scribe Therapeutics and a co-founder of the company.
Benjamin L. Oakes is the President and CEO at Scribe Therapeutics and a co-founder of the company.